glp-1 drugs alternative A new FDA-approved obesity pill could offer a lower-cost to injectable like Ozempic and Mounjaro. In a major clinical trial, people taking the highest dose lost about 11% of GLP-1 Natural Alternatives: Supporting Metabolic
Description
Nearly 90% of Americans are now aware of GLP-1 drugs and their uses.
Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.
Conclusions To conclude, reduced Cmax and delayed tmax of drugs co-administered with GLP1RAs are consistent with the known delayed gastric output by the latter
Propensity score matching (PSM) with 1:1 ratio was employed to create balanced cohorts
We compare Wegovy, Mounjaro, Saxenda and the new oral pill with clinical data.
